



## **Managing Symptom Clusters in Patients on Hemodialysis With CKD-aP: Additional Resources**

### **Efficacy of difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: pooled analysis of KALM-1 and KALM-2 phase 3 studies**

Topf J, Wooldridge T, McCafferty K, et al. Efficacy of difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: pooled analysis of KALM-1 and KALM-2 phase 3 studies. *Kidney Med.* 2022;4(8):100512. doi:10.1016/j.xkme.2022.100512

Link: [https://www.kidneymedicinejournal.org/article/S2590-0595\(22\)00133-9/fulltext](https://www.kidneymedicinejournal.org/article/S2590-0595(22)00133-9/fulltext)

### **Clinically meaningful change in itch intensity scores: an evaluation in patients with chronic kidney disease-associated pruritus**

Vernon M, Ständer S, Munera C, Spencer RH, Menzaghi F. Clinically meaningful change in itch intensity scores: an evaluation in patients with chronic kidney disease-associated pruritus. *J Am Acad Dermatol.* 2021;84(4):1132-1134. doi:10.1016/j.jaad.2020.06.991

Link: [https://www.jaad.org/article/S0190-9622\(20\)32091-0/fulltext](https://www.jaad.org/article/S0190-9622(20)32091-0/fulltext)

### **Managing the symptom burden associated with maintenance dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference**

Mehrotra R, Davison SN, Farrington K, Flythe JE, Foo M, Madero M, Morton RL, Tsukamoto Y, Unruh ML, Cheung M, Jadoul M, Winkelmayer WC, Brown EA; Conference Participants. Managing the symptom burden associated with maintenance dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int.* 2023 Sep;104(3):441-454. doi: 10.1016/j.kint.2023.05.019. Epub 2023 Jun 7. PMID: 37290600.

Link: <https://pubmed.ncbi.nlm.nih.gov/37290600/>

### **A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus**

Fishbane S, Jamal A, Munera C, Wen W, Menzaghi F; KALM-1 Trial Investigators. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus. *N Engl J Med.* 2020 Jan 16;382(3):222-232. doi: 10.1056/NEJMoa1912770. Epub 2019 Nov 8. PMID: 31702883.

Link: <https://pubmed.ncbi.nlm.nih.gov/31702883/>

---

## **Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program**

Fishbane S, Wen W, Munera C, Lin R, Bagal S, McCafferty K, Menzaghi F, Goncalves J. Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program. *Kidney Med.* 2022 Jun 28;4(8):100513. doi: 10.1016/j.xkme.2022.100513. PMID: 36039153; PMCID: PMC9418597.

Link: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418597/>

## **Difelikefalin improves itch-related sleep disruption in patients undergoing haemodialysis**

Weiner DE, Schaufler T, et al. Difelikefalin improves itch-related sleep disruption in patients undergoing haemodialysis. *Nephrology Dialysis Transplantation*, 2023; gfad245. <https://doi.org/10.1093/ndt/gfad245>

<https://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfad245/7424136>

## **Psychometric validation and meaningful change thresholds of the Worst Itching Intensity Numerical Rating Scale for assessing itch in patients with chronic kidney disease-associated pruritus**

Vernon MK, Swett LL, Speck RM, et al. Psychometric validation and meaningful change thresholds of the Worst Itching Intensity Numerical Rating Scale for assessing itch in patients with chronic kidney disease-associated pruritus. *J Patient Rep Outcomes.* 2021;5(1):134. doi:10.1186/s41687-021-00404-z

Link: <https://jpro.springeropen.com/articles/10.1186/s41687-021-00404-z>

## **European S2k guideline on chronic pruritus**

Weisshaar E, Szepietowski JC, Dalgard FJ, et al. European S2k guideline on chronic pruritus. *Acta Derm Venereol.* 2019;99(5):469-506. doi:10.2340/00015555-3164

Link: <https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3164>

---